Theramex is a pharmaceutical company based in London which produces women's health products focusing on contraception, fertility, menopause and osteoporosis.

Theramex
IndustryPharmaceuticals
HeadquartersLondon, United Kingdom
Websitetheramex.com

It was established in 2018 with the acquisition of some of the assets of Teva Active Pharmaceutical Ingredients relating to Theramex Laboratories,[1] a pharmaceutical company which was based in Monaco. Brands include Ovaleap, Zoely, Seasonique, Actonel, Estreva and Lutenyl.

Theramex commercialize its products in more than 80 countries, and has a presence in countries such as the UK, France, Italy, Germany, Spain, Portugal, Australia, Poland, Romania, Slovenia or Brazil, among others.[2]

Robert Stewart is the Chief Executive Officer, since March 2020.[3]

It made an agreement with TherapeuticsMD in 2019 for exclusive licensing and supply rights to Bijuva and Imvexxy outside of the USA, Canada and Israel for which it paid a license fee of $15.5 million.

In 2021, Theramex launched Livogiva,[4] Lundeos[5] (Osteoporosis) and Bijuva[6] (Menopause). That same year Theramex entered Consumer Healthcare Market with Femarelle, a non-hormonal option to treat menopause symptoms.

History[7]Edit

  • 1954: Theramex is founded by Paul Hamel and based in Monaco.
  • 1970: The Theramex brand is established as an independent Women’s Health company, mainly serving France and Italy.
  • 1980: Theramex grows and expands its menopause product range.
  • 1990: Theramex has successfully developed a presence in 15 new markets.
  • 1999: Merck acquires Theramex from François Rougaignon, Paul Hamel Nicolas Guérité and a financial holding company.
  • 2000: Merck KGaA acquires Theramex. The company footprint grows to serve over 25 countries.
  • 2011: Teva Pharmaceuticals acquires Theramex and introduces the Teva Women’s Health brand.
  • 2012: Theramex enters the contraception market with the introduction of a new product. Over the next few years, Theramex develops its product range and expands its portfolio, serving women’s needs in over 50 markets.
  • 2018: Teva Women’s Health is sold to CVC Capital Partners. Theramex emerges as an independent company dedicated to creating important treatments in Women’s Health.
  • 2019: With a presence in key countries including the UK, France, Germany, Italy, Spain, Benelux and Australia, Theramex expands its reach into The Netherlands, Poland, Slovakia and Romania. In June, Theramex completed separation from Teva in all EU markets.
  • 2020: Theramex opens another HQ in Warsaw, Poland. It also awards five grants to fund research into Assisted Reproductive Medicine.
  • 2021 onwards: Theramex plans 3 additional global launches and an expansion of their direct presence into 6 additional markets in Europe and Latin America. Theramex will serve over 80 markets to offer practical and dependable solutions for all women.

ReferencesEdit

  1. ^ yuvraj_wpt19WP. "Teva Completes Acquisition of Theramex | World Pharma Today". Retrieved 9 February 2022.
  2. ^ "About Theramex". Theramex. Retrieved 9 February 2022.
  3. ^ PS, Lakshmi (5 March 2020). "Theramex appoints Robert Stewart as new CEO - Latest Pharmacy News | Business | Magazine - Pharmacy Business". Retrieved 9 February 2022.
  4. ^ "Theramex launches Livogiva®, a new teriparatide pre-filled pen for the treatment of severe osteoporosis". Theramex. 18 January 2021. Retrieved 9 February 2022.
  5. ^ "Theramex launches Lundeos® / Fedivelle®, a new colecalciferol small soft gel capsule for the treatment of Vitamin D deficiency". Theramex. 5 May 2021. Retrieved 9 February 2022.
  6. ^ "Theramex now has approval for Bijuva® / Bijuve® combined hormone therapy treatment for post-menopausal women*". Theramex. 29 September 2021. Retrieved 9 February 2022.
  7. ^ "Our history". Theramex. Retrieved 9 February 2022.